NCT06146309

Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Al-Azhar University · Academic / Other
• Sex: All
• Age: 47 Years – 68 Years
• Healthy volunteers: Accepted

Summary

Several studies have indicated a relation between the development of RVO and elevated intraocular pressure (IOP) and glaucoma \[9\]. Further investigations into the structural alterations in the fellow eyes of individuals with unilateral RVO have revealed that the pRNFL is thinner than in healthy eyes, suggesting that there may be systemic risk factors for both RVO and glaucoma

Conditions

• Branch Retinal Vein Occlusion

Interventions

Type	Name	Description
DRUG	aflibercept (2mg/0.05ml)	Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T

Timeline

• Start date: 2020-12-01
• Primary completion: 2022-07-20
• Completion: 2022-08-01
• First posted: 2023-11-24
• Last updated: 2023-11-24

Locations

1 site across 1 country: Egypt